Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS Co-infections Conference
Studies in Asian women and adult population found people living with HIV switching to Biktarvy® from baseline regimen sustained viral suppression and tolerability
HONG KONG, Oct. 15, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced findings from multiple studies in Asian population that evaluated the safety and...